NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|24641062|ref|NP_572644|]
View 

uncharacterized protein Dmel_CG2111 [Drosophila melanogaster]

Protein Classification

M1 family metallopeptidase( domain architecture ID 10176184)

M1 family metallopeptidase containing an ERAP1-like C-terminal domain with HEAT-like repeats is a zinc-dependent metallopeptidase with an HEXXH motif as part of its active site, similar to aminopeptidase N, a broad specificity aminopeptidase, and glutamyl aminopeptidase, which releases N-terminal glutamate from a peptide

EC:  3.4.11.-
Gene Ontology:  GO:0008237|GO:0008270|GO:0006508
MEROPS:  M1

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
33-487 6.58e-146

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


:

Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 439.71  E-value: 6.58e-146
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062  33 LSYRVDIVTRINQPYqpFGGTVVIDLRSERSTKRIVLNAHDLAIGKrraVTLSDKNGNSVPVSSIQMDIKLSRLTVSLKR 112
Cdd:cd09601   1 LHYDLTLTPDLENFT--FSGSVTITLEVLEPTDTIVLHAKDLTITS---ASLTLKGGSGIIEVTVVTDEETEFLTITLDE 75
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 113 PLKVNVTYSMRVAFTSVLRNDNTGFYSSNYVDHNTTlTQWLAATQFEPNHAREAFPCFDDPIFRTPFKINLAHPYLYRAL 192
Cdd:cd09601  76 TLPPGENYTLSIEFTGKLNDDLRGFYRSSYTDEDGE-TRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHPKGYTAL 154
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 193 SNMPVQRTirHASLKDYVWTQFVESHPMQTYLVAFMISKFDRpgFTSSERSDCPISTWARPDALSQTEFANMVVAPLLSF 272
Cdd:cd09601 155 SNMPPVES--TELEDGWKTTTFETTPPMSTYLVAFVVGDFEY--IESTTKSGVPVRVYARPGKIEQGDFALEVAPKILDF 230
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 273 YEDLFNSTYRQKKIDLVALPDFTFKSKENWGLPAFAEESLLYDSQRSSIDDQQGVARAVAMMVVNQWFGNLVSVAWWHEI 352
Cdd:cd09601 231 YEDYFGIPYPLPKLDLVAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDL 310
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 353 WLKNVFALYLSRFGVHSLRPEWDYQERHALQLYLSVLDYDAHVNTDLVTASVPDESHIWAAYNEIGERKAAVLFEMLHRV 432
Cdd:cd09601 311 WLNEGFATYMEYLAVDKLFPEWNMWDQFVVDELQSALELDSLASSHPIEVPVESPSEISEIFDAISYSKGASVLRMLENF 390
                       410       420       430       440       450
                ....*....|....*....|....*....|....*....|....*....|....*
gi 24641062 433 MGEEAWLTALRRYLVVYANRTATSSDFWDLLQLQVDRNgrlgKGLNITRIMKCWL 487
Cdd:cd09601 391 LGEEVFRKGLRKYLKKHAYGNATTDDLWEALQEASGES----KPLDVKEIMDSWT 441
ERAP1_C pfam11838
ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 ...
578-897 1.31e-58

ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 HEAT-like repeats. This domain forms a concave face that faces towards the active site of the peptidase.


:

Pssm-ID: 463368 [Multi-domain]  Cd Length: 316  Bit Score: 203.66  E-value: 1.31e-58
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   578 WILFNVQHTAPFRVNYDLRNWQLLNKTLADpnkfRLIHRVNRAQLVDDLFSLAWSGDIEYDMALGILGYLEHEDEFVVWV 657
Cdd:pfam11838   1 WVKLNADDTGYYRVNYDPESLAALLEQLLS----KVLSPLDRAGLIDDAFALARAGELSTSDALDLVLAYLNETDYVVWS 76
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   658 ATEISFERINNVAKSNPNYLIFKTYMRLLLERQFKRVISSDLTSSSGNMT-HRPVIIRLACEYELPACVSLARREFMKgt 736
Cdd:pfam11838  77 AALSQLSTLRSLLSADPEYEALKAFLRKLLSPLAEKLGWEAPPGESHLDRqLRALLLSAACSAGDPECVAEAKKLFDA-- 154
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   737 pekggWMTIRE------RETVVCTAVKFGTEGDRDMVESMYKRSNFAAEKESLLTALACSRNVFALQRVLIWTFESSGVR 810
Cdd:pfam11838 155 -----WLDGDDaippdlRWAVYCAAVANGGEAEWDALLERYRDTTSPSEKERALRALAATPDPELLQRALELALDSDEVR 229
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   811 KQNARRTFKAVVSNSMGYRLAKKYVSVNMQNIRNYC--SNSTDKVVNLMTPLiecLSTPKELLYFSKFFKEilRDMNGSE 888
Cdd:pfam11838 230 NQDLRAVIAGLASNPAGRDLAWDFVKENWDALVKRLggGSSLGRLVKGLTPS---FSTEEELDEVEAFFAD--KDTPGLR 304

                  ....*....
gi 24641062   889 RLIKILLER 897
Cdd:pfam11838 305 RALAQALET 313
 
Name Accession Description Interval E-value
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
33-487 6.58e-146

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 439.71  E-value: 6.58e-146
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062  33 LSYRVDIVTRINQPYqpFGGTVVIDLRSERSTKRIVLNAHDLAIGKrraVTLSDKNGNSVPVSSIQMDIKLSRLTVSLKR 112
Cdd:cd09601   1 LHYDLTLTPDLENFT--FSGSVTITLEVLEPTDTIVLHAKDLTITS---ASLTLKGGSGIIEVTVVTDEETEFLTITLDE 75
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 113 PLKVNVTYSMRVAFTSVLRNDNTGFYSSNYVDHNTTlTQWLAATQFEPNHAREAFPCFDDPIFRTPFKINLAHPYLYRAL 192
Cdd:cd09601  76 TLPPGENYTLSIEFTGKLNDDLRGFYRSSYTDEDGE-TRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHPKGYTAL 154
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 193 SNMPVQRTirHASLKDYVWTQFVESHPMQTYLVAFMISKFDRpgFTSSERSDCPISTWARPDALSQTEFANMVVAPLLSF 272
Cdd:cd09601 155 SNMPPVES--TELEDGWKTTTFETTPPMSTYLVAFVVGDFEY--IESTTKSGVPVRVYARPGKIEQGDFALEVAPKILDF 230
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 273 YEDLFNSTYRQKKIDLVALPDFTFKSKENWGLPAFAEESLLYDSQRSSIDDQQGVARAVAMMVVNQWFGNLVSVAWWHEI 352
Cdd:cd09601 231 YEDYFGIPYPLPKLDLVAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDL 310
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 353 WLKNVFALYLSRFGVHSLRPEWDYQERHALQLYLSVLDYDAHVNTDLVTASVPDESHIWAAYNEIGERKAAVLFEMLHRV 432
Cdd:cd09601 311 WLNEGFATYMEYLAVDKLFPEWNMWDQFVVDELQSALELDSLASSHPIEVPVESPSEISEIFDAISYSKGASVLRMLENF 390
                       410       420       430       440       450
                ....*....|....*....|....*....|....*....|....*....|....*
gi 24641062 433 MGEEAWLTALRRYLVVYANRTATSSDFWDLLQLQVDRNgrlgKGLNITRIMKCWL 487
Cdd:cd09601 391 LGEEVFRKGLRKYLKKHAYGNATTDDLWEALQEASGES----KPLDVKEIMDSWT 441
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
25-513 1.77e-73

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 253.80  E-value: 1.77e-73
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062  25 RLPKWLVPLSYRVDIvtRINQPYQPFGGTVVIDLR-SERSTKRIVLNAHDLAIgkrRAVTLsdkNGNSVPVSSiqmdiKL 103
Cdd:COG0308  10 YRPPGYDVTHYDLDL--DLDPATTRLSGTATITFTaTEAPLDSLVLDLKGLEV---TSVTV---DGKPLDFTR-----DG 76
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 104 SRLTVSLKRPLKVNVTYSMRVAFTSVLRNDNTGFYSSNYvdhnTTLTQWLAATQFEPNHAREAFPCFDDPIFRTPFKINL 183
Cdd:COG0308  77 ERLTITLPKPLAPGETFTLEIEYSGKPSNGGEGLYRSGD----PPDGPPYLYTQCEPEGARRWFPCFDHPDDKATFTLTV 152
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 184 AHPYLYRALSNMPVQRTIRHASlkDYVWTQFVESHPMQTYLVAFMISKFDRpgFTSSERSDCPISTWARPDALSQTEFAn 263
Cdd:COG0308 153 TVPAGWVAVSNGNLVSETELGD--GRTTWHWADTQPIPTYLFALAAGDYAV--VEDTFASGVPLRVYVRPGLADKAKEA- 227
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 264 MVVAP-LLSFYEDLFNSTYRQKKIDLVALPDFTFKSKENWGLPAFAEESLLYDsqRSSIDDQQGVARAVAMMVVNQWFGN 342
Cdd:COG0308 228 FESTKrMLDFFEELFGVPYPFDKYDQVAVPDFNFGAMENQGLVTFGEKVLADE--TATDADYERRESVIAHELAHQWFGN 305
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 343 LVSVAWWHEIWLKNVFALYLSRFGVHSLRPEWDYQERHALQLYLSVLDYDAHVNT-DLVTASVPDeshIWAAYNEIGERK 421
Cdd:COG0308 306 LVTCADWDDLWLNEGFATYMEQLFSEDLYGKDAADRIFVGALRSYAFAEDAGPNAhPIRPDDYPE---IENFFDGIVYEK 382
                       410       420       430       440       450       460       470       480
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 422 AAVLFEMLHRVMGEEAWLTALRRYLVVYANRTATSSDFWDLLQlqvDRNGRlgkglNITRIMKCWLGQPGYPLVTVTRNY 501
Cdd:COG0308 383 GALVLHMLRTLLGDEAFRAGLRLYFARHAGGNATTEDFLAALE---EASGR-----DLSAFFDQWLYQAGLPTLEVEYEY 454
                       490
                ....*....|....*
gi 24641062 502 DHRTAI---VSQQRF 513
Cdd:COG0308 455 DADGKVtltLRQTPP 469
ERAP1_C pfam11838
ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 ...
578-897 1.31e-58

ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 HEAT-like repeats. This domain forms a concave face that faces towards the active site of the peptidase.


Pssm-ID: 463368 [Multi-domain]  Cd Length: 316  Bit Score: 203.66  E-value: 1.31e-58
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   578 WILFNVQHTAPFRVNYDLRNWQLLNKTLADpnkfRLIHRVNRAQLVDDLFSLAWSGDIEYDMALGILGYLEHEDEFVVWV 657
Cdd:pfam11838   1 WVKLNADDTGYYRVNYDPESLAALLEQLLS----KVLSPLDRAGLIDDAFALARAGELSTSDALDLVLAYLNETDYVVWS 76
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   658 ATEISFERINNVAKSNPNYLIFKTYMRLLLERQFKRVISSDLTSSSGNMT-HRPVIIRLACEYELPACVSLARREFMKgt 736
Cdd:pfam11838  77 AALSQLSTLRSLLSADPEYEALKAFLRKLLSPLAEKLGWEAPPGESHLDRqLRALLLSAACSAGDPECVAEAKKLFDA-- 154
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   737 pekggWMTIRE------RETVVCTAVKFGTEGDRDMVESMYKRSNFAAEKESLLTALACSRNVFALQRVLIWTFESSGVR 810
Cdd:pfam11838 155 -----WLDGDDaippdlRWAVYCAAVANGGEAEWDALLERYRDTTSPSEKERALRALAATPDPELLQRALELALDSDEVR 229
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   811 KQNARRTFKAVVSNSMGYRLAKKYVSVNMQNIRNYC--SNSTDKVVNLMTPLiecLSTPKELLYFSKFFKEilRDMNGSE 888
Cdd:pfam11838 230 NQDLRAVIAGLASNPAGRDLAWDFVKENWDALVKRLggGSSLGRLVKGLTPS---FSTEEELDEVEAFFAD--KDTPGLR 304

                  ....*....
gi 24641062   889 RLIKILLER 897
Cdd:pfam11838 305 RALAQALET 313
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
261-486 1.26e-44

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 160.53  E-value: 1.26e-44
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   261 FANMVVAPLLSFYEDLFNSTYRQKKIDLVALPDFTFKSKENWGLPAFAEESLLYDSQRSSIDDQQGVARAVAMMVVNQWF 340
Cdd:pfam01433   1 YALEITVKLLEFYEDYFNIPYPLPKYDLVALPDFSAGAMENWGLITYRETLLLYDPGNSSTSDKQRVASVIAHELAHQWF 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   341 GNLVSVAWWHEIWLKNVFALYLSRFGVHSLRPEWDYQERHALQLYLSVLDYDAHVNTDLVTASVPDESHIWAAYNEIGER 420
Cdd:pfam01433  81 GNLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWNIWEQFLLDEVQNAMARDALDSSHPITQNVNDPSEIDDIFDAIPYE 160
                         170       180       190       200       210       220
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 24641062   421 KAAVLFEMLHRVMGEEAWLTALRRYLVVYANRTATSSDFWDLLQlqvdrngRLGKGLNITRIMKCW 486
Cdd:pfam01433 161 KGASVLRMLETLLGEEVFQKGLRSYLKKFQYGNATTEDLWDALS-------EASGPLDVDSFMDTW 219
pepN_strep_liv TIGR02412
aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the ...
156-463 2.17e-29

aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the zinc metallopeptidase family M1 (pfam01433), with a single member characterized in Streptomyces lividans 66 and designated aminopeptidase N. The spectrum of activity may differ somewhat from the aminopeptidase N clade of E. coli and most other Proteobacteria, well separated phylogenetically within the M1 family. The M1 family also includes leukotriene A-4 hydrolase/aminopeptidase (with a bifunctional active site).


Pssm-ID: 274121 [Multi-domain]  Cd Length: 831  Bit Score: 126.06  E-value: 2.17e-29
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   156 TQFEPNHAREAFPCFDDPIFRTPFKINLAHPYLYRALSNmPVQRTIRHASlKDYVWTqFVESHPMQTYLVAFMISKFDRp 235
Cdd:TIGR02412 122 TQFEPADARRVFAVFDQPDLKANFKFSVKAPEDWTVISN-SRETDVTPEP-ADRRWE-FPETPKLSTYLTAVAAGPYHS- 197
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   236 gfTSSERSDCPISTWARPDALSQTEFANM--VVAPLLSFYEDLFNSTYRQKKIDLVALPDFTFKSKENWGLPAFAEESLL 313
Cdd:TIGR02412 198 --VQDESRSYPLGIYARRSLAQYLDADAIftITRQGLAFFHRKFGYPYPFKKYDQIFVPEFNAGAMENAGCVTFAENFLH 275
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   314 ydsqRSSIDDQQGVARAVAMM--VVNQWFGNLVSVAWWHEIWLKNVFALYLsrfGVHSLRPEWDYQE---RHALQLYLSV 388
Cdd:TIGR02412 276 ----RAEATRAEKENRAGVILheMAHMWFGDLVTMRWWNDLWLNESFAEYM---GTLASAEATEYTDawtTFAAQGKQWA 348
                         250       260       270       280       290       300       310
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 24641062   389 LDYDAHVNTDLVTASVPDESHIWAAYNEIGERK-AAVLFEMLHRVmGEEAWLTALRRYLVVYANRTATSSDFWDLL 463
Cdd:TIGR02412 349 YEADQLPTTHPIVADVADLADALSNFDGITYAKgASVLKQLVAWV-GEEAFFAGVNAYFKRHAFGNATLDDLIDSL 423
 
Name Accession Description Interval E-value
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
33-487 6.58e-146

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 439.71  E-value: 6.58e-146
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062  33 LSYRVDIVTRINQPYqpFGGTVVIDLRSERSTKRIVLNAHDLAIGKrraVTLSDKNGNSVPVSSIQMDIKLSRLTVSLKR 112
Cdd:cd09601   1 LHYDLTLTPDLENFT--FSGSVTITLEVLEPTDTIVLHAKDLTITS---ASLTLKGGSGIIEVTVVTDEETEFLTITLDE 75
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 113 PLKVNVTYSMRVAFTSVLRNDNTGFYSSNYVDHNTTlTQWLAATQFEPNHAREAFPCFDDPIFRTPFKINLAHPYLYRAL 192
Cdd:cd09601  76 TLPPGENYTLSIEFTGKLNDDLRGFYRSSYTDEDGE-TRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHPKGYTAL 154
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 193 SNMPVQRTirHASLKDYVWTQFVESHPMQTYLVAFMISKFDRpgFTSSERSDCPISTWARPDALSQTEFANMVVAPLLSF 272
Cdd:cd09601 155 SNMPPVES--TELEDGWKTTTFETTPPMSTYLVAFVVGDFEY--IESTTKSGVPVRVYARPGKIEQGDFALEVAPKILDF 230
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 273 YEDLFNSTYRQKKIDLVALPDFTFKSKENWGLPAFAEESLLYDSQRSSIDDQQGVARAVAMMVVNQWFGNLVSVAWWHEI 352
Cdd:cd09601 231 YEDYFGIPYPLPKLDLVAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDL 310
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 353 WLKNVFALYLSRFGVHSLRPEWDYQERHALQLYLSVLDYDAHVNTDLVTASVPDESHIWAAYNEIGERKAAVLFEMLHRV 432
Cdd:cd09601 311 WLNEGFATYMEYLAVDKLFPEWNMWDQFVVDELQSALELDSLASSHPIEVPVESPSEISEIFDAISYSKGASVLRMLENF 390
                       410       420       430       440       450
                ....*....|....*....|....*....|....*....|....*....|....*
gi 24641062 433 MGEEAWLTALRRYLVVYANRTATSSDFWDLLQLQVDRNgrlgKGLNITRIMKCWL 487
Cdd:cd09601 391 LGEEVFRKGLRKYLKKHAYGNATTDDLWEALQEASGES----KPLDVKEIMDSWT 441
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
25-513 1.77e-73

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 253.80  E-value: 1.77e-73
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062  25 RLPKWLVPLSYRVDIvtRINQPYQPFGGTVVIDLR-SERSTKRIVLNAHDLAIgkrRAVTLsdkNGNSVPVSSiqmdiKL 103
Cdd:COG0308  10 YRPPGYDVTHYDLDL--DLDPATTRLSGTATITFTaTEAPLDSLVLDLKGLEV---TSVTV---DGKPLDFTR-----DG 76
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 104 SRLTVSLKRPLKVNVTYSMRVAFTSVLRNDNTGFYSSNYvdhnTTLTQWLAATQFEPNHAREAFPCFDDPIFRTPFKINL 183
Cdd:COG0308  77 ERLTITLPKPLAPGETFTLEIEYSGKPSNGGEGLYRSGD----PPDGPPYLYTQCEPEGARRWFPCFDHPDDKATFTLTV 152
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 184 AHPYLYRALSNMPVQRTIRHASlkDYVWTQFVESHPMQTYLVAFMISKFDRpgFTSSERSDCPISTWARPDALSQTEFAn 263
Cdd:COG0308 153 TVPAGWVAVSNGNLVSETELGD--GRTTWHWADTQPIPTYLFALAAGDYAV--VEDTFASGVPLRVYVRPGLADKAKEA- 227
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 264 MVVAP-LLSFYEDLFNSTYRQKKIDLVALPDFTFKSKENWGLPAFAEESLLYDsqRSSIDDQQGVARAVAMMVVNQWFGN 342
Cdd:COG0308 228 FESTKrMLDFFEELFGVPYPFDKYDQVAVPDFNFGAMENQGLVTFGEKVLADE--TATDADYERRESVIAHELAHQWFGN 305
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 343 LVSVAWWHEIWLKNVFALYLSRFGVHSLRPEWDYQERHALQLYLSVLDYDAHVNT-DLVTASVPDeshIWAAYNEIGERK 421
Cdd:COG0308 306 LVTCADWDDLWLNEGFATYMEQLFSEDLYGKDAADRIFVGALRSYAFAEDAGPNAhPIRPDDYPE---IENFFDGIVYEK 382
                       410       420       430       440       450       460       470       480
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 422 AAVLFEMLHRVMGEEAWLTALRRYLVVYANRTATSSDFWDLLQlqvDRNGRlgkglNITRIMKCWLGQPGYPLVTVTRNY 501
Cdd:COG0308 383 GALVLHMLRTLLGDEAFRAGLRLYFARHAGGNATTEDFLAALE---EASGR-----DLSAFFDQWLYQAGLPTLEVEYEY 454
                       490
                ....*....|....*
gi 24641062 502 DHRTAI---VSQQRF 513
Cdd:COG0308 455 DADGKVtltLRQTPP 469
ERAP1_C pfam11838
ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 ...
578-897 1.31e-58

ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 HEAT-like repeats. This domain forms a concave face that faces towards the active site of the peptidase.


Pssm-ID: 463368 [Multi-domain]  Cd Length: 316  Bit Score: 203.66  E-value: 1.31e-58
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   578 WILFNVQHTAPFRVNYDLRNWQLLNKTLADpnkfRLIHRVNRAQLVDDLFSLAWSGDIEYDMALGILGYLEHEDEFVVWV 657
Cdd:pfam11838   1 WVKLNADDTGYYRVNYDPESLAALLEQLLS----KVLSPLDRAGLIDDAFALARAGELSTSDALDLVLAYLNETDYVVWS 76
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   658 ATEISFERINNVAKSNPNYLIFKTYMRLLLERQFKRVISSDLTSSSGNMT-HRPVIIRLACEYELPACVSLARREFMKgt 736
Cdd:pfam11838  77 AALSQLSTLRSLLSADPEYEALKAFLRKLLSPLAEKLGWEAPPGESHLDRqLRALLLSAACSAGDPECVAEAKKLFDA-- 154
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   737 pekggWMTIRE------RETVVCTAVKFGTEGDRDMVESMYKRSNFAAEKESLLTALACSRNVFALQRVLIWTFESSGVR 810
Cdd:pfam11838 155 -----WLDGDDaippdlRWAVYCAAVANGGEAEWDALLERYRDTTSPSEKERALRALAATPDPELLQRALELALDSDEVR 229
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   811 KQNARRTFKAVVSNSMGYRLAKKYVSVNMQNIRNYC--SNSTDKVVNLMTPLiecLSTPKELLYFSKFFKEilRDMNGSE 888
Cdd:pfam11838 230 NQDLRAVIAGLASNPAGRDLAWDFVKENWDALVKRLggGSSLGRLVKGLTPS---FSTEEELDEVEAFFAD--KDTPGLR 304

                  ....*....
gi 24641062   889 RLIKILLER 897
Cdd:pfam11838 305 RALAQALET 313
M1 cd09595
Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 ...
35-463 3.07e-48

Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 hydrolase; The model represents the catalytic domains of M1 peptidase family members including aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). All peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile upon activation during catalysis. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. APN expression is dysregulated in many inflammatory diseases and is enhanced in numerous tumor cells, making it a lead target in the development of anti-cancer and anti-inflammatory drugs. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase in LTA4H is as yet unknown, while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals.


Pssm-ID: 341058 [Multi-domain]  Cd Length: 413  Bit Score: 177.25  E-value: 3.07e-48
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062  35 YRVDIVTRINQPYQPFGGTVVIDLRSERSTKRIVLNAHDLAIGKrraVTLsdkNGNSVPVSSIQmDIKLSRLTVSLKRPl 114
Cdd:cd09595   1 YHYDLDLDVDFTTKTLNGTETLTVDASQVGRELVLDLVGLTIHS---VSV---NGAAVDFGERE-HYDGEKLTIPGPKP- 72
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 115 kVNVTYSMRVAFTSVLRNDNTGFYSSNYVDHnttlTQWLAATQFEPNHAREAFPCFDDPIFRTPFKINLAHP-YLYRALS 193
Cdd:cd09595  73 -PGQTFTVRISFEAKPSKNLLGWLWEQTAGK----EKPYLFTQFEATHARRIFPCIDHPAVKATFTVTITTPkKDLLASN 147
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 194 NMPVQRTIRHASLKDYVWTQfveSHPMQTYLVAFMISKFDRPGFTSSERSDCPISTWARPDALSQTEFANMVVAPLLSFY 273
Cdd:cd09595 148 GALVGEETGANGRKTYRFED---TPPIPTYLVAVVVGDLEFKYVTVKSQPRVGLSVYSEPLQVDQAQYAFDATRAALAWF 224
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 274 EDLFNSTYRQKKIDLVALPDFTFKSKENWGLPAFAEESLLYDSQrsSIDDQQGVARAVAMMVVNQWFGNLVSVAWWHEIW 353
Cdd:cd09595 225 EDYFGGPYPLPKYDLLAVPDFNSGAMENPGLITFRTTYLLRSKV--TDTGARSIENVIAHELAHQWFGNLVTMRWWNDLW 302
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 354 LKNVFALYLSRFGVHSLRPEW----DYQERHALQLYLSVLDYDAHVNTDLVTASVPDEshiwaAYNEIGERKAAVLFEML 429
Cdd:cd09595 303 LNEGFAVYYENRIMDATFGTSsrhlDQLSGSSDLNTEQLLEDSSPTSTPVRSPADPDV-----AYDGVTYAKGALVLRML 377
                       410       420       430
                ....*....|....*....|....*....|....
gi 24641062 430 HRVMGEEAWLTALRRYLVVYANRTATSSDFWDLL 463
Cdd:cd09595 378 EELVGEEAFDKGVQAYFNRHKFKNATTDDFIDAL 411
M1_APN cd09602
Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the ...
33-470 5.51e-46

Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the catalytic domain of bacterial and eukaryotic aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341065 [Multi-domain]  Cd Length: 440  Bit Score: 171.54  E-value: 5.51e-46
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062  33 LSYRVDIvtRINQPYQPFGGTVVIDLRSERSTKRIVLnahDLAIGKRRAVTLsdkNGNSVPVSSIQMdiklSRLTVSLKR 112
Cdd:cd09602  16 VSYDLDL--DLTEGAETFRGTVTIRFTLREPGASLFL---DFRGGEVKSVTL---NGRPLDPSAFDG----ERITLPGLL 83
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 113 PLKVNVtysMRVAFTSVLRNDNTGFYSsnYVDH---NTTLTqwlaaTQFEPNHAREAFPCFDDPIFRTPFKINLAHPYLY 189
Cdd:cd09602  84 KAGENT---VVVEFTAPYSSDGEGLHR--FVDPadgETYLY-----TLFEPDDARRVFPCFDQPDLKATFTLTVTAPADW 153
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 190 RALSNMPVQRTIrhaSLKDYVWTQFVESHPMQTYLVAFMISKFDRpgfTSSERSDCPISTWARP-DALSQTEFANM--VV 266
Cdd:cd09602 154 TVISNGPETSTE---EAGGRKRWRFAETPPLSTYLFAFVAGPYHR---VEDEHDGIPLGLYCREsLAEYERDADEIfeVT 227
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 267 APLLSFYEDLFNSTYRQKKIDLVALPDFTFKSKENWGLPAFAEESLLydsqRSSIDDQQGVARAVAMM--VVNQWFGNLV 344
Cdd:cd09602 228 KQGLDFYEDYFGIPYPFGKYDQVFVPEFNFGAMENPGAVTFRESYLF----REEPTRAQRLRRANTILheMAHMWFGDLV 303
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 345 SVAWWHEIWLKNVFALYLSRFGVHSLRPEWDYQERHALQLYLSVLDYDAHVNTDLVTASVPDESHIWAAYNEIGERKAAV 424
Cdd:cd09602 304 TMKWWDDLWLNESFADFMAAKALAEATPFTDAWLTFLLRRKPWAYRADQLPTTHPIAQDVPDLEAAGSNFDGITYAKGAS 383
                       410       420       430       440
                ....*....|....*....|....*....|....*....|....*.
gi 24641062 425 LFEMLHRVMGEEAWLTALRRYLVVYANRTATSSDFWDLLQLQVDRN 470
Cdd:cd09602 384 VLKQLVALVGEEAFRAGLREYFKKHAYGNATLDDLIAALDEASGRD 429
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
261-486 1.26e-44

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 160.53  E-value: 1.26e-44
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   261 FANMVVAPLLSFYEDLFNSTYRQKKIDLVALPDFTFKSKENWGLPAFAEESLLYDSQRSSIDDQQGVARAVAMMVVNQWF 340
Cdd:pfam01433   1 YALEITVKLLEFYEDYFNIPYPLPKYDLVALPDFSAGAMENWGLITYRETLLLYDPGNSSTSDKQRVASVIAHELAHQWF 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   341 GNLVSVAWWHEIWLKNVFALYLSRFGVHSLRPEWDYQERHALQLYLSVLDYDAHVNTDLVTASVPDESHIWAAYNEIGER 420
Cdd:pfam01433  81 GNLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWNIWEQFLLDEVQNAMARDALDSSHPITQNVNDPSEIDDIFDAIPYE 160
                         170       180       190       200       210       220
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 24641062   421 KAAVLFEMLHRVMGEEAWLTALRRYLVVYANRTATSSDFWDLLQlqvdrngRLGKGLNITRIMKCW 486
Cdd:pfam01433 161 KGASVLRMLETLLGEEVFQKGLRSYLKKFQYGNATTEDLWDALS-------EASGPLDVDSFMDTW 219
Peptidase_M1_N pfam17900
Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from ...
31-224 2.96e-41

Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from the M1 family.


Pssm-ID: 465557 [Multi-domain]  Cd Length: 186  Bit Score: 149.80  E-value: 2.96e-41
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062    31 VPLSYRVDIvtRINQPYQPFGGTVVIDLRSERSTKRIVLNAHDLAIgkrRAVTLSDKNG-NSVPVSSIQMDIKLSRLTVS 109
Cdd:pfam17900   1 VPEHYDLDL--KIDLKNFTFSGSVTITLQLNNATNVIVLHASDLTI---RSISLSDEVTsDGVPADFTEDQKDGEKLTIV 75
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   110 LKRPLKVNVTYSMRVAFTSVLRNDNTGFYSSNYVDHNTTltQWLAATQFEPNHAREAFPCFDDPIFRTPFKINLAHPYLY 189
Cdd:pfam17900  76 LPETLNQTGPYTLEIEYSGELNDSMTGFYRSTYTDNGEK--KVLVTTQFEPTDARSAFPCFDEPSVKATFTISIIHPKDY 153
                         170       180       190
                  ....*....|....*....|....*....|....*
gi 24641062   190 RALSNMPVQRTIRHASlkDYVWTQFVESHPMQTYL 224
Cdd:pfam17900 154 TALSNMPVIASEPLEN--GWVITTFEQTPKMSTYL 186
M1_APN_like cd09603
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly ...
33-464 7.90e-39

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly bacterial and some archaeal M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341066 [Multi-domain]  Cd Length: 410  Bit Score: 149.66  E-value: 7.90e-39
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062  33 LSYRVDIvtRINQPYQPFGGTVVIDLRSERSTKRIVLNAHDLAIgkrRAVTLsdkngNSVPVSSIQMDIKlsRLTVSLKR 112
Cdd:cd09603   4 LHYDLDL--DYDPATKSLSGTATITFRATQDLDSLQLDLVGLTV---SSVTV-----DGVPAAFFTHDGD--KLVITLPR 71
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 113 PLKVNVTYSMRVAFTSVlRNDNTGFYSSNYVDHNTTLTqwlAATQFEPNHAREAFPCFDDPIFRTPFKINLAHPYLYRAL 192
Cdd:cd09603  72 PLAAGETFTVTVRYSGK-PRPAGYPPGDGGGWEEGDDG---VWTAGQPEGASTWFPCNDHPDDKATYDITVTVPAGLTVV 147
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 193 SN-MPVQRTIRHASLKDYVWTQfveSHPMQTYLVAFMISKFDRpgFTSSERSDCPISTWARPDALSQTEFANMVVAPLLS 271
Cdd:cd09603 148 SNgRLVSTTTNGGGTTTWHWKM---DYPIATYLVTLAVGRYAV--VEDGSGGGIPLRYYVPPGDAAKAKASFARTPEMLD 222
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 272 FYEDLFnSTYRQKKIDLVALPDFTFkSKENWGLPAFAEESLLYDSQRSSIddqqgVARAVAmmvvNQWFGNLVSVAWWHE 351
Cdd:cd09603 223 FFEELF-GPYPFEKYGQVVVPDLGG-GMEHQTATTYGNNFLNGDRGSERL-----IAHELA----HQWFGDSVTCADWAD 291
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 352 IWLKNVFALYLsrfgvhslrpEWDYQERH----ALQLYLSVLDYDAHVNTDLVTASVPDE----SHIwaaYNeigerKAA 423
Cdd:cd09603 292 IWLNEGFATYA----------EWLWSEHKggadAYRAYLAGQRQDYLNADPGPGRPPDPDdlfdRDV---YQ-----KGA 353
                       410       420       430       440
                ....*....|....*....|....*....|....*....|.
gi 24641062 424 VLFEMLHRVMGEEAWLTALRRYLVVYANRTATSSDFWDLLQ 464
Cdd:cd09603 354 LVLHMLRNLLGDEAFFAALRAYLARYAHGNVTTEDFIAAAE 394
pepN_strep_liv TIGR02412
aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the ...
156-463 2.17e-29

aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the zinc metallopeptidase family M1 (pfam01433), with a single member characterized in Streptomyces lividans 66 and designated aminopeptidase N. The spectrum of activity may differ somewhat from the aminopeptidase N clade of E. coli and most other Proteobacteria, well separated phylogenetically within the M1 family. The M1 family also includes leukotriene A-4 hydrolase/aminopeptidase (with a bifunctional active site).


Pssm-ID: 274121 [Multi-domain]  Cd Length: 831  Bit Score: 126.06  E-value: 2.17e-29
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   156 TQFEPNHAREAFPCFDDPIFRTPFKINLAHPYLYRALSNmPVQRTIRHASlKDYVWTqFVESHPMQTYLVAFMISKFDRp 235
Cdd:TIGR02412 122 TQFEPADARRVFAVFDQPDLKANFKFSVKAPEDWTVISN-SRETDVTPEP-ADRRWE-FPETPKLSTYLTAVAAGPYHS- 197
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   236 gfTSSERSDCPISTWARPDALSQTEFANM--VVAPLLSFYEDLFNSTYRQKKIDLVALPDFTFKSKENWGLPAFAEESLL 313
Cdd:TIGR02412 198 --VQDESRSYPLGIYARRSLAQYLDADAIftITRQGLAFFHRKFGYPYPFKKYDQIFVPEFNAGAMENAGCVTFAENFLH 275
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   314 ydsqRSSIDDQQGVARAVAMM--VVNQWFGNLVSVAWWHEIWLKNVFALYLsrfGVHSLRPEWDYQE---RHALQLYLSV 388
Cdd:TIGR02412 276 ----RAEATRAEKENRAGVILheMAHMWFGDLVTMRWWNDLWLNESFAEYM---GTLASAEATEYTDawtTFAAQGKQWA 348
                         250       260       270       280       290       300       310
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 24641062   389 LDYDAHVNTDLVTASVPDESHIWAAYNEIGERK-AAVLFEMLHRVmGEEAWLTALRRYLVVYANRTATSSDFWDLL 463
Cdd:TIGR02412 349 YEADQLPTTHPIVADVADLADALSNFDGITYAKgASVLKQLVAWV-GEEAFFAGVNAYFKRHAFGNATLDDLIDSL 423
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
52-463 6.22e-18

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 87.51  E-value: 6.22e-18
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062  52 GTVVIDLRS-ERSTKRIVLNAHDLAIGKrraVTLSDknGNSVPVSSIQMDIKL-SRLTVSLKRPLKVNVTYSMRVAFTSv 129
Cdd:cd09599  31 GSATLTLEVlQDGADELVLDTRDLDISS---VTVNG--GKELKFELGPRDPVLgSALTITLPSPLAKGDTFKVKIEYST- 104
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 130 lrndntgfyssnyvDHNTTLTQWLAA------------TQFEPNHAREAFPCFDDPIFRTPFKINLAHPYLYRAL-SNMP 196
Cdd:cd09599 105 --------------TPQATALQWLTPeqtagkkhpylfTQCQAIHARSLFPCQDTPSVKSTYSATVTVPKGLTALmSALR 170
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 197 VQRTIrHASLKDYVWTQFVeshPMQTYLVAFMISKFDrpgFTS-SERSdcpiSTWARPDAL--SQTEFANMvvAPLLSFY 273
Cdd:cd09599 171 TGEKE-EAGTGTYTFEQPV---PIPSYLIAIAVGDLE---SREiGPRS----GVWAEPSVVdaAAEEFADT--EKFLKAA 237
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 274 EDLFnSTYRQKKIDLVALPD-FTFKSKENWGLpAFAEESLL-YDsqRSSIDDqqgvaraVAMMVVNQWFGNLVSVAWWHE 351
Cdd:cd09599 238 EKLY-GPYVWGRYDLLVLPPsFPYGGMENPCL-TFATPTLIaGD--RSLVDV-------IAHEIAHSWSGNLVTNANWEH 306
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 352 IWLKNVFALYLSRFGVHSLRPEwDYQERHALQ----LYLSVLDYDA-HVNTDLVTASV---PDEshiwaAYNEIGERKAA 423
Cdd:cd09599 307 FWLNEGFTVYLERRILERLYGE-EYRQFEAILgwkdLQESIKEFGEdPPYTLLVPDLKgvdPDD-----AFSSVPYEKGF 380
                       410       420       430       440
                ....*....|....*....|....*....|....*....|
gi 24641062 424 VLFEMLHRVMGEEAWLTALRRYLVVYANRTATSSDFWDLL 463
Cdd:cd09599 381 QFLYYLEQLGGREVFDPFLRAYFKKFAFQSIDTEDFKDFL 420
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
52-502 2.00e-17

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 87.14  E-value: 2.00e-17
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062    52 GTVVIDLRSERSTKR-IVLNAHDLAIGKrraVTLsdkNGNSVPVS-SIQMDIKLSRLTVSLKRPLKVNVTYSMRVAFTSV 129
Cdd:TIGR02411  31 GSVTFTLKSLTDNLNkLVLDTSYLDIQK---VTI---NGLPADFAiGERKEPLGSPLTISLPIATSKNDEFVLNISFSTT 104
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   130 lrndntgfyssnyvDHNTTLtQWLAATQ------------FEPNHAREAFPCFDDPIFRTPFKINLAHPYLYRAlSNMPV 197
Cdd:TIGR02411 105 --------------PKCTAL-QWLNPEQtsgkkhpylfsqCQAIHARSLFPCQDTPSVKSTYTAEVESPLPVLM-SGIRD 168
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   198 QRTIRHASLkdYVWTQFVeshPMQTYLVAFMISKFD-RPgftSSERSdcpiSTWARPDAL--SQTEFANMvVAPLLSFYE 274
Cdd:TIGR02411 169 GETSNDPGK--YLFKQKV---PIPAYLIAIASGDLAsAP---IGPRS----TVYSEPEQLekCQYEFEND-TEKFIKTAE 235
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   275 DLFnSTYRQKKIDLVALPD-FTFKSKENWGLpAFAEESLLyDSQRSSIDdqqgvarAVAMMVVNQWFGNLVSVAWWHEIW 353
Cdd:TIGR02411 236 DLI-FPYEWGQYDLLVLPPsFPYGGMENPNL-TFATPTLI-AGDRSNVD-------VIAHELAHSWSGNLVTNCSWEHFW 305
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   354 LKNVFALYLSRFGVHSLRPEwdyQERH--------ALQLYLSVLDYDaHVNTDLV---TASVPDESHIWAAYneigERKA 422
Cdd:TIGR02411 306 LNEGWTVYLERRIIGRLYGE---KTRHfsaligwgDLQESVKTLGET-PEFTKLVvdlKDNDPDDAFSSVPY----EKGF 377
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062   423 AVLFEMLHRVMGEEAWLTALRRYLVVYANRTATSSDFWDLLqlqVDRNGRLGKGLNITRI-MKCWLGQPGYPlvTVTRNY 501
Cdd:TIGR02411 378 NFLFYLEQLLGGPAEFDPFLRHYFKKFAYKSLDTYQFKDAL---YEYFKDKKKVDKLDAVdWETWLYSPGMP--PVKPNF 452

                  .
gi 24641062   502 D 502
Cdd:TIGR02411 453 D 453
M1_APN_like cd09604
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains ...
338-464 9.69e-04

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains bacterial M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341067 [Multi-domain]  Cd Length: 440  Bit Score: 42.65  E-value: 9.69e-04
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 24641062 338 QWFGNLVSV-----AWWHEIWlkNVFA--LYLSRFGvhslrPEWDYQERHALQLYLSVLDY-DAHVNTDLVTASvPDESH 409
Cdd:cd09604 304 QWFYGIVGNderrePWLDEGL--ATYAesLYLEEKY-----GKEAADELLGRRYYRAYARGpGGPINLPLDTFP-DGSYY 375
                        90       100       110       120       130
                ....*....|....*....|....*....|....*....|....*....|....*
gi 24641062 410 IWAAYNeigerKAAVLFEMLHRVMGEEAWLTALRRYLVVYANRTATSSDFWDLLQ 464
Cdd:cd09604 376 SNAVYS-----KGALFLEELREELGDEAFDKALREYYRRYKFKHPTPEDFFRTAE 425
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH